- Home
- ONTO vs MDGL Comparison
ONTO vs MDGL Comparison
Compare ONTO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONTO | MDGL |
|---|---|---|
| Founded | 1940 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.0B |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ONTO | MDGL |
|---|---|---|
| Price | $189.91 | $443.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $229.38 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 862.9K | 327.9K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 2.78 | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $26.63 | $58.70 |
| Revenue Next Year | $16.26 | $46.88 |
| P/E Ratio | $66.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $89.40 | $265.00 |
| 52 Week High | $232.49 | $615.00 |
Technical Indicators
Market Signals| Indicator | ONTO | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 45.40 |
| Support Level | $178.40 | $416.43 |
| Resistance Level | $229.81 | $446.51 |
| Average True Range (ATR) | 10.36 | 15.97 |
| MACD | -3.59 | 3.09 |
| Stochastic Oscillator | 25.80 | 78.35 |
Price Performance
Historical ComparisonAbout ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.